Antibacterial Drugs Market to Exceed $46 billion by 2015: Report
According to a new report from market research firm Global Industry Analysts Inc., the world market for antibacterial drugs will exceed $46 billion within five years. A constant rise in the proportion of the elderly population, new therapies against resistant bacteria, and a growing demand for Glycopeptides and Carbapenems are expected to drive market growth. The report also points out, however, that the future of the market is likely to be influenced by two key factors -- antibiotic resistance and generic competition.
Antibacterials treat an array of bacterial infections that range from minor to life threatening problems. High market maturity, patent expiries, generic drug penetration, and shortened product lifecycle due to bacterial drug resistance characterize the global market for antibacterial drugs, the report notes. Patent expiries of several leading drugs in recent years have commoditized the market. In order to remain competitive, many players are extensively engaged in the development of an anti-MRSA treatment, which can be used along with conventional antibacterials.
Asia-Pacific dominates the world antibacterial drugs market, and, according to the report, the region will likely remain the fastest growing market in coming years. Cephalosporins represents the largest segment in the global antibacterial drugs market, but Macrolides is expected to be the fastest growing segment, driven by immunomodulatory effects and expanded indications, the report says.
Key players profiled in the report include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Daiichi Sankyo Co. Ltd., Elan Corp., Eli Lilly and Company, GlaxoSmithKline Plc, Hoffman-La Roche, Johnson & Johnson, Merck & Co., Pfizer Inc., and Wyeth Pharmaceuticals Inc.
For more information on "Antibacterial Drugs: A Global Strategic Business Report," visit www.strategyr.com/Antibacterial_Drugs_Market_Report.asp.